Engflag

Carbolith

Quick links to important sections

Carbolith

Carbolith_ID

Method of action: Antipsychotic, Psychoanaleptics, Psycholeptics, Sedative

Treatment option: Bipolar Affective Disorder, Bipolar Disorder, Mania

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carbolith

Quick Facts

Property Description
Active Ingredient Lithium Carbonate (Lithii carbonas)
Form Capsules, Tablets (oral preparations)
Pharmacological Class Mood Stabilizer, Antimanic Agent
General Purpose To promote emotional stability
Origin Synthetic, Inorganic Compound

What Type of Medicine is Carbolith?

Carbolith is a trade name for a prescription-only medication whose active substance is Lithium Carbonate (Lithii carbonas), formally classified as a Mood Stabilizer and Antimanic Agent. Its active component is the Lithium cation, an inorganic compound and an alkali-metal salt. This categorization reflects its use in regulating the balance within the central nervous system. The medication is included on the World Health Organization’s list of Essential Medicines, which designates it as one of the most effective and safe agents necessary in a health system.

Composition and Available Forms

Lithium Carbonate is a single-ingredient product, typically prepared as an oral pharmaceutical preparation in the form of capsules or tablets. The medication is designed exclusively for oral administration. Formulations often include both immediate-release and controlled-release versions, which are critical due to the compound’s narrow therapeutic range. These varying forms are essential for managing the compound's absorption rate, aiming to achieve and maintain optimal levels in the blood, thereby sustaining the stabilizing effect. The sustained-release salts may offer better tolerability, though both types are commonly used to manage the Lithium cation levels.

General Purpose: How It Achieves Emotional Stability

The general purpose of this medication is to promote emotional equilibrium. It acts by subtly modulating how nerve cells process signals, affecting the movement of ions like sodium and adjusting the activity of various neurotransmitter systems within the central nervous system. By gently altering these foundational communication pathways, Lithium Carbonate works to mitigate severe mood shifts and promote stability, serving as a cornerstone for long-term emotional management.

Regulatory References

  1. WHO Essential Medicines

What side effects are possible with Carbolith?

Possible Side Effects and Safety Information for Carbolith

The safety profile for Carbolith (lithium carbonate) is based on official government regulatory documents and is structured around the risk of systemic toxicity, necessitating rigorous monitoring.

Documented Adverse Reactions

Side effects are categorized by frequency and the body system affected:

Classification Examples of Documented Reactions
Common Side Effects Fine hand tremor, increased thirst (polydipsia), increased urination (polyuria), nausea, and general discomfort. These may be more prominent during initial therapy.
System-Organ Classes Effects documented across the Nervous System, Gastrointestinal Tract, Kidneys/Urinary System, and Endocrine System (thyroid/parathyroid).

Serious Adverse Reactions and Key Organ Risks

Officially documented serious risks include:

  • Acute Lithium Toxicity: A life-threatening risk closely related to high serum concentrations. Symptoms can progress to coma, convulsions, and renal failure.
  • Nephrotoxicity (Kidney Damage): Long-term use is associated with a risk of diminished kidney function and chronic tubulointerstitial nephropathy.
  • Thyroid Dysfunction: The drug can cause hypothyroidism and hyperparathyroidism.
  • Cardiac Concerns: Documented potential for unmasking or aggravating Brugada Syndrome, a hereditary heart condition.

Population and Safety Restrictions

Safety statements define strict boundaries for use:

  • Contraindications: Carbolith is restricted in patients with severe renal or cardiovascular disease, severe dehydration, or sodium depletion.
  • Pregnancy and Lactation: Use during pregnancy may pose a risk of cardiac anomalies (e.g., Ebstein's anomaly) to the fetus. It is excreted in breast milk.
  • Monitoring Requirements: Due to the narrow therapeutic range and toxicity risk, regular monitoring of serum lithium concentrations, renal function, and thyroid function is required.

Overdose and Emergency Response

The official regulatory profile for Carbolith (Lithium Carbonate) describes overdose as a continuum of toxicity, with symptoms progressing in severity. Initial manifestations often involve the gastrointestinal system, typically presenting as nausea, vomiting, and persistent diarrhea. These rapidly progress to severe neurological signs, including intensifying tremor, lack of coordination (ataxia), confusion, slurred speech, and muscle twitching.

Required Emergency Actions

Situation Regulator-Mandated Action
Early Signs of Toxicity Discontinue the medication and contact a physician immediately (e.g., persistent diarrhea, mild tremor, drowsiness) [Source 1.2, 1.9].
Life-Threatening Symptoms Immediate emergency assistance is required for symptoms such as fainting, abnormal heart beats (cardiac abnormalities), or shortness of breath [Source 1.2].

Severe, life-threatening outcomes are documented, including the potential for Serotonin Syndrome, Encephalopathic Syndrome leading to possible irreversible brain damage, and cardiovascular abnormalities. Management is supportive, as no specific antidote for lithium poisoning is known. Treatment focuses on eliminating the ion; hemodialysis (kidney dialysis) is the required procedure for severe cases, coupled with mandatory serial serum lithium determinations for monitoring [Source 1.8, 2.1]. Regulatory labeling also notes that geriatric patients may exhibit toxicity at lower serum concentrations [Source 2.2].

Therapeutic Uses of Carbolith

What Carbolith Treats: Main Uses and Benefits

Carbolith (Lithium Carbonate) is a medication commonly used across key therapeutic domains to promote emotional stability and manage severe mood instability. The active ingredient, lithium, is generally used for managing manic episodes of Bipolar Disorder and is applied as maintenance treatment for individuals with this diagnosis. It is applied in clinical settings marked by heightened patient distress and recurrent symptomatic episodes.

Key Therapeutic Domains and Symptom Relief

This medication is relevant for easing symptoms associated with acute or episodic changes in mood. It primarily addresses conditions characterized by periods of heightened symptoms, specifically including Bipolar Disorder (both acute mania and mixed episodes) and recurrent Major Depressive Disorder (used as augmentation therapy). It is considered relevant for managing symptom clusters that may become intense or disruptive, such as motor hyperactivity, pressure of speech, and episodes of aggressiveness.

Quick Fact: Relief for Behavioral Dysregulation Lithium may be part of symptomatic management for high-intensity manifestations that interfere with daily functioning, assisting with maintaining functional stability by providing supportive relief when symptoms interfere with routine activities.

It is commonly used for patients facing recurrent mood instability, where additional symptomatic support is needed. The therapeutic benefit may assist with acute mania by contributing to easing the overall symptom load during crisis, and supports patients during difficult episodes by managing the frequency and intensity of severe mood swings, which may assist with reducing the risk of self-harm in vulnerable patients.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Carbolith — Official Regulatory Information

Official regulatory documents define strict limitations on the populations eligible for Carbolith (Lithium Carbonate) use, primarily based on organ function and physiological stability.

Eligibility Scope Regulatory Rule (Official Status)
Populations Contraindicated Patients with severe renal disease, significant cardiovascular disease (e.g., cardiac rhythm disorders, Brugada syndrome), severe dehydration, or sodium depletion are contraindicated.
Organ-Function Restrictions Use requires caution in patients with mild or moderate renal impairment, necessitating close monitoring. Untreated hypothyroidism is also a formal contraindication.
Age-Related Rules Approved use starts at 7 years of age and older for Immediate-Release formulations, and 12 years of age and older for Extended-Release. Use in children below these minimum ages is not established. Older adults require cautious dose selection.
Reproductive Status The medicine may cause fetal harm (e.g., cardiac anomalies) if used during pregnancy, and is generally avoided in the first trimester. Use is not recommended or contraindicated in breastfeeding mothers.
Conditional Use Patients concurrently receiving diuretics or on a low-sodium diet may only use the medicine with extreme caution due to very high risk of toxicity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Carbolith (Lithium Carbonate) is primarily defined by substances that alter its renal clearance and those that cause pharmacodynamic synergy within the central nervous system, as documented in governmental regulatory sources.

Documented Exposure-Altering Interactions

Interacting Agents Officially Documented Effect
Diuretics (Thiazides) & ACE Inhibitors Significantly decrease lithium renal clearance, raising the risk of severe toxicity. This combination is generally restricted or avoided.
NSAIDs (e.g., Indomethacin, COX-2 Inhibitors) Reduce the excretion of lithium, leading to increased serum concentrations and requiring close monitoring.
Metronidazole (Antibiotic) Documented to increase lithium plasma concentrations.
Caffeine & Theophylline (Xanthines) May increase lithium excretion, potentially leading to decreased effectiveness.

Pharmacodynamic and Substance Interactions

Interacting Agents Officially Documented Outcome
Serotonergic Agents (SSRIs, SNRIs, Triptans, St. John’s Wort) Increased risk of developing Serotonin Syndrome.
Antipsychotics (Neuroleptics, e.g., Haloperidol) Increased risk of serious neurologic adverse reactions, including encephalopathic syndrome.
Low Sodium Diet/Dehydration Decreased lithium clearance and a heightened risk of lithium toxicity.

Population-Specific Notes: The official prescribing information notes that geriatric patients and individuals with renal impairment are more susceptible to interaction-induced toxicity due to the likelihood of diminished lithium clearance.

Mechanism of Action

Carbolith (lithium) exerts its pharmacodynamic effects through multiple mechanistic domains that modulate neuronal function. It primarily influences intracellular signaling cascades by acting as a non-competitive inhibitor of inositol monophosphatase (IMPase). This interaction interferes with the recycling of inositol, a critical second messenger, which results in dampened signal amplification within overactive neurons and alters overall neural signaling patterns. The drug is also an inhibitor of Glycogen Synthase Kinase-3 (GSK-3), an enzyme pivotal in regulating processes like cellular growth and stress response. Inhibition of GSK-3 influences molecular pathways that govern cell structural integrity and long-term regulatory control. Furthermore, Carbolith, acting as an ion analog, alters the movement and function of native ions, including sodium and calcium, which affects action potential generation and neurotransmitter release. This action modifies the balance between excitatory pathways, such as those mediated by glutamate, and inhibitory pathways, like those mediated by GABA, thereby adjusting the net excitability profile of central neural pathways.

Dosage and Administration Information

How to Use Carbolith: Official Administration Guidelines

Carbolith, which contains Lithium Carbonate, is exclusively administered via the oral route. It is available as immediate-release (IR) and extended-release (ER) capsules or tablets, and as an oral solution, with strengths ranging from 150 mg to 600 mg.

Dosing and Frequency

Usage involves a systematic dose adjustment, known as titration, beginning with a low dose that is gradually increased to achieve stable levels in the blood. Standard dosing for acute control typically reaches up to 1800 mg per day in divided doses, while maintenance dosing often ranges from 900 mg to 1200 mg per day.

The total daily amount is usually administered in divided doses (two or three times daily) to maintain consistent concentrations. However, certain extended-release formulations may be prescribed as a single dose regimen for long-term control.

Administration Requirements and Handling

Feature Official Administration Guideline
Timing in Relation to Meals May be taken with food to minimize common gastrointestinal discomfort.
Fluid and Salt Intake Patients must maintain adequate fluid intake (2500 to 3000 mL) and a normal diet including salt during treatment, especially during the initial phase.
Special Handling Extended-release tablets must be swallowed whole and must not be crushed or chewed.
Monitoring Blood samples for serum lithium level checks must be drawn 8 to 12 hours after the last dose (trough level).

Population-Specific Use

Official instructions mandate dose adjustments for specific groups. Older adults typically require lower initial and maintenance dosages. The drug requires careful, reduced dosing in patients with renal impairment. Approved pediatric use is specified for children 7 years and older (IR forms) or 12 years and older (ER forms).

Recent Clinical Evidence

The research basis for Carbolith (Lithium Carbonate) in Bipolar Disorder consists primarily of systematic reviews and meta-analyses that pool data from randomized controlled trials (RCTs). This research was studied for use in conditions characterized by fluctuating or episodic manifestations. Researchers examined outcomes related to acute stabilization during periods of increased symptom activity, and maintenance to address future episodes.

In the acute phase, studies monitored how quickly manic symptoms evolved in the observed populations. For maintenance, research explored how symptoms evolved over extended periods, with findings describing patterns where the time elapsed before a new manic episode was documented compared to control groups. However, studies showed that the outcomes related to depressive episodes were less consistently measured than those related to manic episodes.

Maintenance studies, which featured follow-up periods ranging from months to years, observed daily-life functioning and monitored outcomes reflecting daily functioning or activity level. While these studies contribute to the broader evidence landscape, they do not determine whether an individual will respond similarly over time.

Carbolith was also evaluated in clinical trials for Recurrent Major Depressive Disorder Augmentation, specifically as an addition to standard antidepressant therapy in adults who were previously unmanaged by standard treatment. Furthermore, specific research was studied for outcomes related to suicidal behavior. This evidence is derived from both systematic reviews of RCTs and large-scale observational studies.

While the evidence base is extensive, the research highlights areas that are still uncertain. Comparative evidence is lacking against all newer medications, and limited information for long-term outcomes is available for certain subgroups. Research is ongoing to help contextualize patient experience and to better characterize predictors of response.

How should Carbolith be stored and disposed of?

Official Storage and Disposal Requirements

Carbolith (Lithium Carbonate) must be stored strictly according to official regulatory specifications to maintain product stability and safety. The labeled storage temperature is Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F). The product must be protected from moisture and heat; therefore, it must be kept in the original container and be tightly closed.

All Lithium Carbonate medications must be stored out of the sight and reach of children.

Disposal of unused or expired medicine should follow official guidance. The preferred method is a community drug take-back program. If this is unavailable, the medicine should be mixed with an undesirable substance (e.g., dirt) and placed in a sealed container before discarding it in household trash. Personal information must be scratched out from the label prior to disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagCanada

Equivalent of Carbolith found in:

A-Z Index: